Interrupted time series analysis in clinical researchMATOWE, Lloyd K; LEISTER, Cathie A; CRIVERA, Concetta et al.The Annals of pharmacotherapy. 2003, Vol 37, Num 7-8, pp 1110-1116, issn 1060-0280, 7 p.Article

Comparative Bioavailability Study of Single-Dose Film-Coated and Sugar-Coated Ethionamide Tablets in Healthy VolunteersKORTH-BRADLEY, Joan M; MAYER, Philip; MANSFIELD, Debra et al.Clinical therapeutics. 2014, Vol 36, Num 6, pp 982-987, issn 0149-2918, 6 p.Article

The Effect of a High-Fat Breakfast on the Pharmacokinetics of Moxidectin in Healthy Male Subjects: A Randomized Phase I TrialKORTH-BRADLEY, Joan M; PARKS, Virginia; CHALON, Stephan et al.The American journal of tropical medicine and hygiene. 2012, Vol 86, Num 1, pp 122-125, issn 0002-9637, 4 p.Article

Excretion of Moxidectin into Breast Milk and Pharmacokinetics in Healthy Lactating WomenKORTH-BRADLEY, Joan M; PARKS, Virginia; CHALON, Stephan et al.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 11, pp 5200-5204, issn 0066-4804, 5 p.Article

Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg doseRODVOLD, Keith A; GOTFRIED, Mark H; CWIK, Michael et al.Journal of antimicrobial chemotherapy (Print). 2006, Vol 58, Num 6, pp 1221-1229, issn 0305-7453, 9 p.Article

Chiral bioequivalence : Effect of absorption rate on racemic etodolacBONI, Joseph P; KORTH-BRADLEY, Joan M; RICHARDS, Lyette S et al.Clinical pharmacokinetics. 2000, Vol 39, Num 6, pp 459-469, issn 0312-5963Article

Tigecycline Does Not Prolong Corrected QT Intervals in Healthy SubjectsKORTH-BRADLEY, Joan M; MCGOVERN, Paul C; SALAGEANU, Joanne et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 4, pp 1895-1901, issn 0066-4804, 7 p.Article

Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapseBERGER, Mark S; LEOPOLD, Lance H; DOWELL, James A et al.Investigational new drugs. 2002, Vol 20, Num 4, pp 395-406, issn 0167-6997, 12 p.Article

Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicinKORTH-BRADLEY, Joan M; DOWELL, James A; KING, S. Peter et al.Pharmacotherapy. 2001, Vol 21, Num 10, pp 1175-1180, issn 0277-0008Conference Paper

The pharmacokinetics of etanercept in patients with heart failureSORAN, Ozlem; FELDMAN, Arthur M; SCHNEIDER, Virginia M et al.British journal of clinical pharmacology. 2001, Vol 51, Num 2, pp 191-192, issn 0306-5251Article

Optimising piperacillin/tazobactam dosing in paediatricsTORNØE, Christoffer W; TWORZYANSKI, Jeffrey J; IMOISILI, Menfo A et al.International journal of antimicrobial agents. 2007, Vol 30, Num 4, pp 320-324, issn 0924-8579, 5 p.Article

Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpointsAMBROSE, Paul G; MEAGHER, Alison K; PASSARELL, Julie A et al.Diagnostic microbiology and infectious disease. 2009, Vol 63, Num 1, pp 38-42, issn 0732-8893, 5 p.Article

Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumoniaFREIRE, Antonio T; MELNYK, Vasyl; KORTH-BRADLEY, Joan M et al.Diagnostic microbiology and infectious disease. 2010, Vol 68, Num 2, pp 140-151, issn 0732-8893, 12 p.Article